116 related articles for article (PubMed ID: 38846985)
1. P53/NANOG balance; the leading switch between poorly to well differentiated status in liver cancer cells.
Ranjbar-Niavol F; Rezaei N; Zhao Y; Mirzaei H; Hassan M; Vosough M
Front Oncol; 2024; 14():1377761. PubMed ID: 38846985
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma.
Nakano A; Watanabe N; Nishizaki Y; Takashimizu S; Matsuzaki S
Hepatol Res; 2003 Feb; 25(2):158-165. PubMed ID: 12644052
[TBL] [Abstract][Full Text] [Related]
3. NUMB phosphorylation destabilizes p53 and promotes self-renewal of tumor-initiating cells by a NANOG-dependent mechanism in liver cancer.
Siddique HR; Feldman DE; Chen CL; Punj V; Tokumitsu H; Machida K
Hepatology; 2015 Nov; 62(5):1466-79. PubMed ID: 26174965
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic regulation of pluripotent genes mediates stem cell features in human hepatocellular carcinoma and cancer cell lines.
Wang XQ; Ng RK; Ming X; Zhang W; Chen L; Chu AC; Pang R; Lo CM; Tsao SW; Liu X; Poon RT; Fan ST
PLoS One; 2013; 8(9):e72435. PubMed ID: 24023739
[TBL] [Abstract][Full Text] [Related]
5. Mitophagy Controls the Activities of Tumor Suppressor p53 to Regulate Hepatic Cancer Stem Cells.
Liu K; Lee J; Kim JY; Wang L; Tian Y; Chan ST; Cho C; Machida K; Chen D; Ou JJ
Mol Cell; 2017 Oct; 68(2):281-292.e5. PubMed ID: 29033320
[TBL] [Abstract][Full Text] [Related]
6. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression.
Lin T; Chao C; Saito S; Mazur SJ; Murphy ME; Appella E; Xu Y
Nat Cell Biol; 2005 Feb; 7(2):165-71. PubMed ID: 15619621
[TBL] [Abstract][Full Text] [Related]
7. Differential effectiveness of tyrosine kinase inhibitors in 2D/3D culture according to cell differentiation, p53 status and mitochondrial respiration in liver cancer cells.
Rodríguez-Hernández MA; Chapresto-Garzón R; Cadenas M; Navarro-Villarán E; Negrete M; Gómez-Bravo MA; Victor VM; Padillo FJ; Muntané J
Cell Death Dis; 2020 May; 11(5):339. PubMed ID: 32382022
[TBL] [Abstract][Full Text] [Related]
8. Notch1 signaling sensitizes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human hepatocellular carcinoma cells by inhibiting Akt/Hdm2-mediated p53 degradation and up-regulating p53-dependent DR5 expression.
Wang C; Qi R; Li N; Wang Z; An H; Zhang Q; Yu Y; Cao X
J Biol Chem; 2009 Jun; 284(24):16183-16190. PubMed ID: 19376776
[TBL] [Abstract][Full Text] [Related]
9. RAB27A-dependent release of exosomes by liver cancer stem cells induces Nanog expression in their differentiated progenies and confers regorafenib resistance.
Huang H; Hou J; Liu K; Liu Q; Shen L; Liu B; Lu Q; Zhang N; Che L; Li J; Jiang S; Wang B; Wen Q; Hu L; Gao J
J Gastroenterol Hepatol; 2021 Dec; 36(12):3429-3437. PubMed ID: 34258777
[TBL] [Abstract][Full Text] [Related]
10. Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma.
Qin HX; Nan KJ; Yang G; Jing Z; Ruan ZP; Li CL; Xu R; Guo H; Sui CG; Wei YC
World J Gastroenterol; 2005 May; 11(18):2709-13. PubMed ID: 15884108
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/Snail signaling.
Yin X; Zhang BH; Zheng SS; Gao DM; Qiu SJ; Wu WZ; Ren ZG
J Hematol Oncol; 2015 Mar; 8():23. PubMed ID: 25879771
[TBL] [Abstract][Full Text] [Related]
12. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma.
Shan J; Shen J; Liu L; Xia F; Xu C; Duan G; Xu Y; Ma Q; Yang Z; Zhang Q; Ma L; Liu J; Xu S; Yan X; Bie P; Cui Y; Bian XW; Qian C
Hepatology; 2012 Sep; 56(3):1004-14. PubMed ID: 22473773
[TBL] [Abstract][Full Text] [Related]
13. Relationship between p53 overexpression and the proliferative activity in hepatocellular carcinoma.
Itoh T; Shiro T; Seki T; Nakagawa T; Wakabayashi M; Inoue K; Okamura A
Int J Mol Med; 2000 Aug; 6(2):137-42. PubMed ID: 10891556
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog controls neural stem cells through p53-independent regulation of Nanog.
Po A; Ferretti E; Miele E; De Smaele E; Paganelli A; Canettieri G; Coni S; Di Marcotullio L; Biffoni M; Massimi L; Di Rocco C; Screpanti I; Gulino A
EMBO J; 2010 Aug; 29(15):2646-58. PubMed ID: 20581804
[TBL] [Abstract][Full Text] [Related]
15. RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma.
Ye J; Liang R; Bai T; Lin Y; Mai R; Wei M; Ye X; Li L; Wu F
J Exp Clin Cancer Res; 2018 Sep; 37(1):212. PubMed ID: 30176896
[TBL] [Abstract][Full Text] [Related]
16. Differential localization of LGR5 and Nanog in clusters of colon cancer stem cells.
Amsterdam A; Raanan C; Schreiber L; Freyhan O; Fabrikant Y; Melzer E; Givol D
Acta Histochem; 2013 May; 115(4):320-9. PubMed ID: 23098761
[TBL] [Abstract][Full Text] [Related]
17. 5-Aminoimidazole-4-carboxyamide ribonucleoside induces G(1)/S arrest and Nanog downregulation via p53 and enhances erythroid differentiation.
Chae HD; Lee MR; Broxmeyer HE
Stem Cells; 2012 Feb; 30(2):140-9. PubMed ID: 22076938
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of PRAME Suppresses Proliferation and Promotes Apoptosis in Hepatocellular Carcinoma Through the Activation of P53 Mediated Pathway.
Zhu H; Wang J; Yin J; Lu B; Yang Q; Wan Y; Jia C
Cell Physiol Biochem; 2018; 45(3):1121-1135. PubMed ID: 29439259
[TBL] [Abstract][Full Text] [Related]
19. Inhibition mechanism of a newly cloned candidate tumor suppressor gene JST during hepatocarcinogenesis and its abnormal expression in human hepatocellular carcinoma from Qidong liver cancer risk area, China.
Dong-Dong L; Xi-Ran Z
Hepatogastroenterology; 2004; 51(56):515-25. PubMed ID: 15086194
[TBL] [Abstract][Full Text] [Related]
20. p53 expression is associated with tumor stage, grade and subtype in patients with hepatocellular carcinoma.
Rahadiani N; Stephanie M; Perkasa AG; Handjari DR; Krisnuhoni E
Mol Clin Oncol; 2023 Jul; 19(1):54. PubMed ID: 37323246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
